Project Details
Description
Multiresistant bacteria are a global problem to human health. The number of new
antibiotics reaching the market is decreasing year by year, while the number of
resistant bacteria increases. We have developed a new class of antibiotics
belonging to the pleuromutilins and found it to be very potent towards both MRSA
and VRE - both important human pathogens and multi-resistant bacteria. This is
extremely promising, and with this application, we will further develop the class in
terms of efficacy, stability, and toxicity, and make a compound ready for
commercialization and potentially human use.
antibiotics reaching the market is decreasing year by year, while the number of
resistant bacteria increases. We have developed a new class of antibiotics
belonging to the pleuromutilins and found it to be very potent towards both MRSA
and VRE - both important human pathogens and multi-resistant bacteria. This is
extremely promising, and with this application, we will further develop the class in
terms of efficacy, stability, and toxicity, and make a compound ready for
commercialization and potentially human use.
| Status | Finished |
|---|---|
| Effective start/end date | 01/07/2021 → 30/06/2022 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.